This document provides an overview of Good Laboratory Practice (GLP) principles established by the Organization for Economic Co-operation and Development (OECD). GLP was created in response to cases of fraudulent laboratory practices and aims to ensure the quality and validity of non-clinical safety studies. The key principles include requirements for test facility organization, quality assurance programs, facilities, equipment, test systems, test items, standard operating procedures, study conduct, reporting, and record keeping. Following GLP aims to yield data that accurately reflect study results and ensure international acceptance of safety tests.
The document discusses Good Laboratory Practice (GLP), which are quality standards that regulate the conduct of laboratory studies related to health and safety. It provides background on GLP, explaining that GLP was created by the FDA in the 1970s after investigations found fraudulent activities and poor practices in toxicology labs. The objectives of GLP are to ensure data submitted are an accurate reflection of study results and that data is traceable. GLP provides a framework for planning, conducting, monitoring, recording and reporting laboratory studies while maintaining quality assurance.
This document provides summaries of ICH Q series guidelines related to pharmaceutical quality. The Q series addresses topics such as stability testing, analytical validation, impurities, pharmacopoeias, quality of biotechnological products, specifications for drug substances and products, good manufacturing practices, pharmaceutical development, quality risk management, and pharmaceutical quality systems. The guidelines provide recommendations for testing protocols, validation procedures, acceptance criteria, and ensuring quality across the lifecycle of drug manufacturing and development.
The Center for Drug Evaluation and Research (CDER) is responsible for protecting and promoting public health by ensuring the safety and effectiveness of human drugs. CDER oversees new drug development and reviews marketing applications, monitors drug safety after approval, and ensures quality in manufacturing. CDER's mission is to ensure that drugs are safe and effective for their intended use through activities like reviewing new drug applications, communicating drug information to health professionals and consumers, and facilitating innovation in drug development.
PPT ON GOOD LABORATORY PRACTICES (GLP)GOVIND YADAV
The document discusses Good Laboratory Practice (GLP) guidelines. It notes that in the 1970s, the FDA discovered many cases of poor laboratory practices and fraudulent activities in the US. This led to the establishment of GLP principles to ensure reliable and high-quality non-clinical safety studies. GLP guidelines cover facilities, equipment, standard operating procedures, personnel training, record-keeping, and quality assurance programs. The goal of GLP is to ensure that experimental data accurately reflect the results and that studies are conducted in accordance with the principles of good laboratory practice.
The document discusses Good Laboratory Practice (GLP), which are quality standards that regulate the conduct of laboratory studies related to health and safety. It provides background on GLP, including that GLP was created by the FDA in the 1970s in response to cases of fraudulent laboratory practices. The key objectives of GLP are to ensure laboratory study data is accurate, traceable, and can be relied upon for regulatory decision making. GLP establishes requirements for facilities, equipment, personnel, methods, records, and management to ensure the integrity of all safety data generated during nonclinical health and environmental safety studies.
Presentation on good laoratory practice (glp)AshishVerma571
GLP is a formal regulation established by the FDA in 1978 that provides a framework for conducting laboratory studies in a planned, monitored and documented manner. It was introduced in response to cases of fraud in safety data submitted to the FDA. GLP requires that facilities, equipment, personnel and study plans be qualified and that studies be conducted according to standard operating procedures to ensure the quality and integrity of data. Studies must be properly designed, performed, monitored, recorded, reported and archived to comply with GLP.
The document discusses Good Laboratory Practice (GLP), which are quality standards that regulate the conduct of laboratory studies related to health and safety. It provides background on GLP, explaining that GLP was created by the FDA in the 1970s after investigations found fraudulent activities and poor practices in toxicology labs. The objectives of GLP are to ensure data submitted are an accurate reflection of study results and that data is traceable. GLP provides a framework for planning, conducting, monitoring, recording and reporting laboratory studies while maintaining quality assurance.
This document provides summaries of ICH Q series guidelines related to pharmaceutical quality. The Q series addresses topics such as stability testing, analytical validation, impurities, pharmacopoeias, quality of biotechnological products, specifications for drug substances and products, good manufacturing practices, pharmaceutical development, quality risk management, and pharmaceutical quality systems. The guidelines provide recommendations for testing protocols, validation procedures, acceptance criteria, and ensuring quality across the lifecycle of drug manufacturing and development.
The Center for Drug Evaluation and Research (CDER) is responsible for protecting and promoting public health by ensuring the safety and effectiveness of human drugs. CDER oversees new drug development and reviews marketing applications, monitors drug safety after approval, and ensures quality in manufacturing. CDER's mission is to ensure that drugs are safe and effective for their intended use through activities like reviewing new drug applications, communicating drug information to health professionals and consumers, and facilitating innovation in drug development.
PPT ON GOOD LABORATORY PRACTICES (GLP)GOVIND YADAV
The document discusses Good Laboratory Practice (GLP) guidelines. It notes that in the 1970s, the FDA discovered many cases of poor laboratory practices and fraudulent activities in the US. This led to the establishment of GLP principles to ensure reliable and high-quality non-clinical safety studies. GLP guidelines cover facilities, equipment, standard operating procedures, personnel training, record-keeping, and quality assurance programs. The goal of GLP is to ensure that experimental data accurately reflect the results and that studies are conducted in accordance with the principles of good laboratory practice.
The document discusses Good Laboratory Practice (GLP), which are quality standards that regulate the conduct of laboratory studies related to health and safety. It provides background on GLP, including that GLP was created by the FDA in the 1970s in response to cases of fraudulent laboratory practices. The key objectives of GLP are to ensure laboratory study data is accurate, traceable, and can be relied upon for regulatory decision making. GLP establishes requirements for facilities, equipment, personnel, methods, records, and management to ensure the integrity of all safety data generated during nonclinical health and environmental safety studies.
Presentation on good laoratory practice (glp)AshishVerma571
GLP is a formal regulation established by the FDA in 1978 that provides a framework for conducting laboratory studies in a planned, monitored and documented manner. It was introduced in response to cases of fraud in safety data submitted to the FDA. GLP requires that facilities, equipment, personnel and study plans be qualified and that studies be conducted according to standard operating procedures to ensure the quality and integrity of data. Studies must be properly designed, performed, monitored, recorded, reported and archived to comply with GLP.
The document defines Good Laboratory Practice (GLP) and describes its key principles and objectives. GLP provides a framework for conducting non-clinical health and environmental safety studies to ensure reliability and reproducibility. The main elements of GLP include qualified personnel, adequate facilities and equipment, standard operating procedures, test and control article handling, and documentation and record keeping. GLP aims to assure accurate study results and promote international acceptance of safety tests.
This document provides an introduction to Good Laboratory Practices (GLP). It defines GLP as a quality system for non-clinical health and environmental safety studies. The document outlines the history of GLP, elements of GLP including standard operating procedures and quality assurance units, objectives of GLP, scope of GLP application, and principles of GLP. It describes GLP as having four pillars: management, quality assurance, study director, and national compliance monitoring authorities. The goal of GLP is to ensure quality and integrity in laboratory studies submitted to regulatory authorities.
GLP provides a quality system for non-clinical laboratory studies to ensure reliability of results. It aims to develop quality test data and avoid duplication through adherence to standards for organization, personnel, facilities, equipment, operation of studies and reporting. GLP was created by the FDA in 1978 and adopted internationally by organizations like OECD to facilitate acceptance of study data across regions.
The document provides an introduction to Good Laboratory Practice (GLP). It discusses how in the 1970s, the FDA discovered many cases of poor laboratory practices and fraudulent activities in the US. This led to the formal creation of GLP regulations by the FDA and OECD to ensure quality and reliability in non-clinical safety studies. The key principles of GLP include standardized operations in areas like facilities, equipment, test systems, protocols, record-keeping and reporting to ensure study data accurately represent results. Compliance with GLP aims to produce high-quality data and gain mutual acceptance of studies internationally.
GLP principles were created by the USFDA and OECD to establish standardized practices in non-clinical laboratory studies due to past malpractices. GLP aims to ensure study data accurately reflects results and is traceable by regulating an organization's quality system, facilities, equipment, test systems, operating procedures, personnel qualifications, protocols, records, reports and archiving. Key aspects of GLP include establishing responsibilities for management, study directors and quality assurance units and having standard operating procedures for conducting studies, testing facilities, equipment, reagents and animal care in accordance with approved protocols.
This document provides an overview of Good Laboratory Practice (GLP) standards. It defines GLP as a set of principles that provide a framework for conducting laboratory studies. GLP was established by the FDA in the 1970s after discovering fraudulent activities and poor practices in laboratories. GLP applies to nonclinical safety studies on chemicals, pharmaceuticals, and other products submitted to regulatory authorities. The document outlines the key components of GLP, including requirements for organization, personnel, facilities, equipment, testing operations, record keeping, and quality assurance. It also summarizes the various subparts and responsibilities defined in the 21 CFR part 58 GLP regulations.
This document provides an overview of ICH guidelines related to quality (Q series). It describes the composition and objectives of ICH, which aims to harmonize technical requirements for pharmaceutical registration among regulators and industry in the EU, Japan, and US. The key points are that ICH guidelines are divided into four categories, including the Q series which relates to chemical and pharmaceutical quality. The Q series guidelines cover topics like stability testing, analytical validation, impurities, and residual solvents. The goal is to establish common standards for assessing safety, quality and efficacy of medicines.
Auditing of vendors and production departmentArpitSuralkar
This document outlines procedures for auditing vendors that produce capsules and sterile products. It discusses the benefits of vendor audits such as cost savings, process improvements, and risk reduction. The document describes the vendor selection process and provides a checklist for auditing vendors, which includes evaluating their premises, personnel, documentation, validation procedures, samples, stability studies, and drug recall processes. The goal of vendor audits is to inspect vendors' quality management systems and ensure they meet requirements for producing capsules and sterile medical products.
The document discusses Good Laboratory Practices (GLP). It provides definitions and history of GLP. GLP refers to a quality management system for laboratories conducting non-clinical safety studies. It aims to ensure reliability and integrity of test data. Key aspects of GLP include organization, SOPs, facilities, equipment, test systems, study planning and reporting, archiving. Non-compliance can result in disqualification and rejection of study data by regulatory agencies.
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
“A GMP is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product”.
The document provides guidelines for handling out of specification test results as outlined by the USFDA. It defines an out of specification result as one that falls outside the defined test limits. It discusses the USFDA's OOS guidelines published in 2006 and notes that quality units should have a defined SOP for addressing OOS results. The SOP scope should be well defined and investigations into OOS results should be thorough, timely, unbiased, well documented, and scientifically sound. Laboratory investigations should check for errors and, if none are found, a phase II investigation including retesting and investigation at the plant may be initiated. Tools like 5M, 5 whys, DMAIC and root cause analysis should be used to identify
The International Council for Harmonisation (ICH) brings together regulatory authorities and the pharmaceutical industry to discuss technical requirements for drug registration. ICH has produced guidelines on quality, safety, efficacy, and multidisciplinary topics. The quality guidelines cover stability testing, analytical validation, impurities, Good Manufacturing Practice, and quality risk management. Together, the ICH guidelines aim to harmonize technical requirements across regions to provide efficient drug development and approval.
The document is a presentation on post-approval changes to bulk active chemicals. It discusses FDA guidance called BACPAC (Bulk Active Chemicals & Post Approval Changes) which provides recommendations for post-approval changes to drug substance synthesis, including site, scale and equipment changes as well as specification and manufacturing process changes. The guidance covers assessing equivalence after changes and determining the appropriate reporting category based on the potential effects of changes.
This document discusses various quality control and documentation procedures in the pharmaceutical industry. It includes 3 key points:
1. It discusses the importance of documentation in defining specifications, methods, providing an audit trail and ensuring authorized personnel have necessary information. This includes documents like specifications, batch production records, SOPs etc.
2. It describes procedures for developing key documents like master formulas, batch manufacturing records, audit plans and reports. This ensures uniform processes and allows tracing of batch history.
3. It discusses quality audits which systematically examine if quality activities comply with arrangements and objectives. This includes internal audits as well as those imposed by regulators or customers.
Documentation is an integral part of good manufacturing practices. It defines a system of information and control so that risks so inherent in misinterpretation and/or error in oral communication are minimized.
GLP (Good Laboratory Practice) is a quality system concerned with conducting non-clinical safety studies. It aims to ensure studies are accurately reported and not fraudulent. GLP has principles for organization, personnel, facilities, test systems, operating procedures, performance and reporting of studies. India's National GLP Compliance Monitoring Authority monitors adherence. GLP compliance certification is required for safety studies of products like pesticides, pharmaceuticals and food additives, and helps protect human and environmental health while facilitating international trade.
Good Laboratory Practice (GLP) regulations were created by the FDA in the 1970s after discovering fraudulent activities and poor lab practices that undermined the quality and integrity of data submitted to the FDA. GLP aims to ensure that studies are conducted properly according to standardized operating procedures and that accurate records are kept. This allows data from non-clinical studies to be reliably submitted to regulatory authorities. Key aspects of GLP include requirements for facilities, test systems, operating procedures, personnel qualifications, quality assurance programs, and record keeping. Following GLP helps assure reproducibility and quality of results.
GLP (Good Laboratory Practice) is a set of principles established by the FDA in 1978 to ensure the quality and integrity of safety data submitted for regulatory purposes. Key aspects of GLP include standardized facilities, equipment, test systems, operating procedures, personnel responsibilities, and record keeping. Studies must follow detailed study plans and SOPs. Quality assurance programs verify compliance. Proper storage and retention of raw data, samples, and reports is also required under GLP guidelines.
OECD principles of Good laboratory practice. this ppt include the basic and necessary information required for OECD GLP guideline . Content is taken from official site
The document defines Good Laboratory Practice (GLP) and describes its key principles and objectives. GLP provides a framework for conducting non-clinical health and environmental safety studies to ensure reliability and reproducibility. The main elements of GLP include qualified personnel, adequate facilities and equipment, standard operating procedures, test and control article handling, and documentation and record keeping. GLP aims to assure accurate study results and promote international acceptance of safety tests.
This document provides an introduction to Good Laboratory Practices (GLP). It defines GLP as a quality system for non-clinical health and environmental safety studies. The document outlines the history of GLP, elements of GLP including standard operating procedures and quality assurance units, objectives of GLP, scope of GLP application, and principles of GLP. It describes GLP as having four pillars: management, quality assurance, study director, and national compliance monitoring authorities. The goal of GLP is to ensure quality and integrity in laboratory studies submitted to regulatory authorities.
GLP provides a quality system for non-clinical laboratory studies to ensure reliability of results. It aims to develop quality test data and avoid duplication through adherence to standards for organization, personnel, facilities, equipment, operation of studies and reporting. GLP was created by the FDA in 1978 and adopted internationally by organizations like OECD to facilitate acceptance of study data across regions.
The document provides an introduction to Good Laboratory Practice (GLP). It discusses how in the 1970s, the FDA discovered many cases of poor laboratory practices and fraudulent activities in the US. This led to the formal creation of GLP regulations by the FDA and OECD to ensure quality and reliability in non-clinical safety studies. The key principles of GLP include standardized operations in areas like facilities, equipment, test systems, protocols, record-keeping and reporting to ensure study data accurately represent results. Compliance with GLP aims to produce high-quality data and gain mutual acceptance of studies internationally.
GLP principles were created by the USFDA and OECD to establish standardized practices in non-clinical laboratory studies due to past malpractices. GLP aims to ensure study data accurately reflects results and is traceable by regulating an organization's quality system, facilities, equipment, test systems, operating procedures, personnel qualifications, protocols, records, reports and archiving. Key aspects of GLP include establishing responsibilities for management, study directors and quality assurance units and having standard operating procedures for conducting studies, testing facilities, equipment, reagents and animal care in accordance with approved protocols.
This document provides an overview of Good Laboratory Practice (GLP) standards. It defines GLP as a set of principles that provide a framework for conducting laboratory studies. GLP was established by the FDA in the 1970s after discovering fraudulent activities and poor practices in laboratories. GLP applies to nonclinical safety studies on chemicals, pharmaceuticals, and other products submitted to regulatory authorities. The document outlines the key components of GLP, including requirements for organization, personnel, facilities, equipment, testing operations, record keeping, and quality assurance. It also summarizes the various subparts and responsibilities defined in the 21 CFR part 58 GLP regulations.
This document provides an overview of ICH guidelines related to quality (Q series). It describes the composition and objectives of ICH, which aims to harmonize technical requirements for pharmaceutical registration among regulators and industry in the EU, Japan, and US. The key points are that ICH guidelines are divided into four categories, including the Q series which relates to chemical and pharmaceutical quality. The Q series guidelines cover topics like stability testing, analytical validation, impurities, and residual solvents. The goal is to establish common standards for assessing safety, quality and efficacy of medicines.
Auditing of vendors and production departmentArpitSuralkar
This document outlines procedures for auditing vendors that produce capsules and sterile products. It discusses the benefits of vendor audits such as cost savings, process improvements, and risk reduction. The document describes the vendor selection process and provides a checklist for auditing vendors, which includes evaluating their premises, personnel, documentation, validation procedures, samples, stability studies, and drug recall processes. The goal of vendor audits is to inspect vendors' quality management systems and ensure they meet requirements for producing capsules and sterile medical products.
The document discusses Good Laboratory Practices (GLP). It provides definitions and history of GLP. GLP refers to a quality management system for laboratories conducting non-clinical safety studies. It aims to ensure reliability and integrity of test data. Key aspects of GLP include organization, SOPs, facilities, equipment, test systems, study planning and reporting, archiving. Non-compliance can result in disqualification and rejection of study data by regulatory agencies.
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
“A GMP is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product”.
The document provides guidelines for handling out of specification test results as outlined by the USFDA. It defines an out of specification result as one that falls outside the defined test limits. It discusses the USFDA's OOS guidelines published in 2006 and notes that quality units should have a defined SOP for addressing OOS results. The SOP scope should be well defined and investigations into OOS results should be thorough, timely, unbiased, well documented, and scientifically sound. Laboratory investigations should check for errors and, if none are found, a phase II investigation including retesting and investigation at the plant may be initiated. Tools like 5M, 5 whys, DMAIC and root cause analysis should be used to identify
The International Council for Harmonisation (ICH) brings together regulatory authorities and the pharmaceutical industry to discuss technical requirements for drug registration. ICH has produced guidelines on quality, safety, efficacy, and multidisciplinary topics. The quality guidelines cover stability testing, analytical validation, impurities, Good Manufacturing Practice, and quality risk management. Together, the ICH guidelines aim to harmonize technical requirements across regions to provide efficient drug development and approval.
The document is a presentation on post-approval changes to bulk active chemicals. It discusses FDA guidance called BACPAC (Bulk Active Chemicals & Post Approval Changes) which provides recommendations for post-approval changes to drug substance synthesis, including site, scale and equipment changes as well as specification and manufacturing process changes. The guidance covers assessing equivalence after changes and determining the appropriate reporting category based on the potential effects of changes.
This document discusses various quality control and documentation procedures in the pharmaceutical industry. It includes 3 key points:
1. It discusses the importance of documentation in defining specifications, methods, providing an audit trail and ensuring authorized personnel have necessary information. This includes documents like specifications, batch production records, SOPs etc.
2. It describes procedures for developing key documents like master formulas, batch manufacturing records, audit plans and reports. This ensures uniform processes and allows tracing of batch history.
3. It discusses quality audits which systematically examine if quality activities comply with arrangements and objectives. This includes internal audits as well as those imposed by regulators or customers.
Documentation is an integral part of good manufacturing practices. It defines a system of information and control so that risks so inherent in misinterpretation and/or error in oral communication are minimized.
GLP (Good Laboratory Practice) is a quality system concerned with conducting non-clinical safety studies. It aims to ensure studies are accurately reported and not fraudulent. GLP has principles for organization, personnel, facilities, test systems, operating procedures, performance and reporting of studies. India's National GLP Compliance Monitoring Authority monitors adherence. GLP compliance certification is required for safety studies of products like pesticides, pharmaceuticals and food additives, and helps protect human and environmental health while facilitating international trade.
Good Laboratory Practice (GLP) regulations were created by the FDA in the 1970s after discovering fraudulent activities and poor lab practices that undermined the quality and integrity of data submitted to the FDA. GLP aims to ensure that studies are conducted properly according to standardized operating procedures and that accurate records are kept. This allows data from non-clinical studies to be reliably submitted to regulatory authorities. Key aspects of GLP include requirements for facilities, test systems, operating procedures, personnel qualifications, quality assurance programs, and record keeping. Following GLP helps assure reproducibility and quality of results.
GLP (Good Laboratory Practice) is a set of principles established by the FDA in 1978 to ensure the quality and integrity of safety data submitted for regulatory purposes. Key aspects of GLP include standardized facilities, equipment, test systems, operating procedures, personnel responsibilities, and record keeping. Studies must follow detailed study plans and SOPs. Quality assurance programs verify compliance. Proper storage and retention of raw data, samples, and reports is also required under GLP guidelines.
OECD principles of Good laboratory practice. this ppt include the basic and necessary information required for OECD GLP guideline . Content is taken from official site
Good Laboratory Practice (GLP) is a formal set of regulations established by the US FDA in 1976 to ensure that non-clinical safety studies are of high quality and are accurately reported. GLP covers the organizational processes and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, reported and archived. It aims to assure that study data accurately reflect the results obtained during the study and allows for mutual acceptance of data between countries. GLP requires strict adherence to standard operating procedures, record keeping, facilities management, and quality assurance programs to ensure the integrity of preclinical safety testing.
This document provides an overview of Good Laboratory Practices (GLP). It discusses that GLP aims to assure regulatory authorities that safety study data submitted to them are reliable and accurate. The document traces the history and development of GLP from cases of poor laboratory practices in the 1970s. It describes the key principles of GLP including requirements for facilities, equipment, test systems, personnel responsibilities, standard operating procedures, and reporting of study results. Adherence to GLP aims to produce high quality and integrity of nonclinical safety data.
Good Laboratory Practices Pharmaceutical Quality AssuranceShrikantKavitake1
This document provides information about Good Laboratory Practices (GLP). It discusses that GLP was created by the FDA in 1978 after cases of fraud were discovered in toxicology labs. GLP provides a framework to ensure uniformity, consistency, reliability and quality of non-clinical safety studies. It outlines principles for organization, personnel, facilities, test systems, standard operating procedures, and archiving to ensure integrity of study data and compliance. The objectives of GLP are to assure regulatory authorities that submitted data accurately reflects study results and can be relied upon for risk assessments.
This document outlines the principles of Good Laboratory Practices (GLP). GLP provides a framework for conducting laboratory studies and ensuring quality and integrity of data. The key points covered include defining GLP and its purpose of certifying valid study steps. Ten GLP principles are described relating to laboratory organization, facilities, equipment, test systems, methods, and record keeping. Maintaining proper documentation, conducting quality assurance inspections, and retaining records and materials are emphasized. In conclusion, following GLP guidelines helps produce high quality data and ensures proper laboratory management.
GLP is a formal FDA regulation created in 1978 that provides principles for conducting laboratory studies in a standard, consistent manner. It aims to ensure quality and integrity of data submitted to the FDA. Key GLP principles include requirements for test facility organization, quality assurance programs, facilities, equipment, test systems, standard operating procedures, study conduct, reporting, and record keeping. GLP helps provide reliable results and protects study integrity and data for regulating products like drugs and pesticides.
GLP (Good Laboratory Practice) is a quality system for non-clinical health and environmental safety studies. It aims to ensure quality, uniformity, consistency, reproducibility, traceability, reliability and integrity of test data. Key aspects of GLP include standardized procedures for conducting studies, recording and reporting data, and archiving records and materials. GLP was established after fraud was discovered in toxicology lab data submitted to regulators. Adherence to GLP helps ensure the reliability and integrity of non-clinical safety studies.
GCP, GLP and GCLP are international guidelines for clinical trials, non-clinical studies, and clinical laboratory testing. GCP ensures the rights, safety and well-being of clinical trial subjects. GLP provides standards for non-clinical laboratory studies to ensure reliable data. GCLP bridges GCP and GLP by providing quality standards for analytical laboratories involved in clinical trials to ensure reliable and traceable data. Adherence to these guidelines helps ensure ethical and scientific standards in research and regulatory acceptance of study results.
The document discusses Good Laboratory Practice (GLP) which are quality standards for conducting non-clinical safety studies. It provides definitions and background information. Specifically:
1. GLP are principles defined by the OECD for organizing and conducting non-clinical safety studies of products in a quality, standardized manner.
2. The OECD published the GLP principles in 1981 to ensure safety studies are well-planned, performed, monitored and reported in accordance with best practices.
3. GLP principles apply primarily to safety studies on pharmaceuticals submitted for regulatory approval and cover many types of toxicity and safety pharmacology studies.
The Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) was established under Section 15(1) of the Prevention of Cruelty to Animals Act 1960.
GLP is a quality system concerned with the organizational process and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported. GLP principles include. Organization and Personnel. Management-Responsibilities.
A bioassay is an analytical method to determine the concentration or potency of a substance by its effect on living animals or plants, or on living cells or tissues. A bioassay can be either quantal or quantitative, direct or indirect.
GLP (Good Laboratory Practice) is a formal regulation created by the FDA in 1978 to ensure the quality and integrity of safety data involved in regulatory decision making. It was developed because of cases of poor laboratory practices, fraudulent activities, and inaccurate reporting of studies. GLP principles provide a framework for planning, conducting, monitoring, recording, reporting and archiving laboratory studies according to standard operating procedures. Following GLP helps ensure the reliability and integrity of data, provides better control and guidelines for laboratory processes, and gives companies conducting research a quality image in the global market.
This document discusses Good Laboratory Practice (GLP) standards and guidelines. It begins by defining GLP and explaining that GLP regulations are established by organizations like OECD and ISO to ensure quality, correctness, traceability and integrity of non-clinical study data. Key aspects of GLP include standard operating procedures (SOPs) and a Quality Assurance Unit (QAU). The document then outlines specific requirements for GLP like defining responsibilities, following SOPs, ensuring proper facilities, equipment calibration and personnel training. It describes the scope of GLP applications and differences between GLP, Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP). The roles of SOPs and QAU in maintaining standards are explained
The document discusses Good Laboratory Practice (GLP) regulations, which were established in the 1970s in response to concerns about poor laboratory practices that were discovered during FDA investigations of toxicology labs in the US. The GLP principles were created by the FDA in 1976 and formed the basis of international GLP standards developed by the OECD. The primary aims of GLP are to ensure the quality and integrity of non-clinical safety data submitted to regulatory authorities and to facilitate the mutual acceptance of data among countries. GLP covers how non-clinical safety studies should be planned, performed, monitored, recorded and reported in key areas like facilities, equipment, test systems, standard operating procedures and record keeping.
This document provides an overview of Good Laboratory Practices (GLP). It discusses that GLP is an FDA regulation that provides a framework for planning, conducting, monitoring, recording, and reporting nonclinical laboratory studies. The document outlines the history of GLP and why it was created, describes key aspects of GLP such as organization, personnel, facilities, equipment, test systems, and record keeping. It also discusses objectives of GLP and highlights an important example of a lab that was found to be fraudulent and engaged in poor practices.
Good Laboratory Practice. Quality Control and quality AssuranceYogita Ahire
The document discusses Good Laboratory Practices (GLP). It defines GLP as a quality system concerned with organizational processes and conditions for planning, performing, monitoring, recording, and reporting nonclinical studies. GLP aims to assure regulatory authorities that study data submitted is valid. The key principles of GLP include having qualified personnel and facilities, documented standard operating procedures, raw data collection, and a quality assurance program. GLP provides guidelines for conducting studies and maintaining accurate records to help ensure the safety and integrity of research.
Good Laboratory Practice (GLP) regulations are applied to non-clinical safety of study items contained in pharmaceutical products, cosmetic products, veterinary drugs, devices as well as food additives. The purpose of testing these items is to obtain information on their safety with respect to human health and environment. GLP is also required for registration purpose and licensing of pharmaceuticals, pesticides, food additives, veterinary drug products and some bio-products.
This presentation is for the pharmacy, nursing and medical students. this presentation is about brief discussion on good laboratory practice (GLP) for the exam point of view.
Good Laboratory Practices (GLP) are a quality system for research laboratories aimed at ensuring test data reliability and integrity. GLP principles provide a framework for planning, performing, monitoring, recording, reporting and archiving laboratory studies. GLP was established in response to cases of fraud and poor practices in toxicology labs that generated invalid safety data. Key elements of GLP include standardized operations, qualified personnel, documented procedures, quality control, auditing and record keeping. GLP guidelines help regulatory authorities by assuring data submitted to assess product safety is scientifically valid.
Good laboratory practices (GLP) are quality standards for conducting non-clinical health and environmental safety studies. GLP aims to ensure studies are properly planned, performed, monitored, recorded and reported. It was introduced after the FDA found issues like fraud, inadequate facilities and equipment, and inaccurate reports during inspections of toxicology labs in the 1970s. Key aspects of GLP include adequate resources, characterization of test items and systems, standard operating procedures, record keeping of raw data and reports, archiving, and quality assurance through audits and inspections. GLP promotes reliable, repeatable and auditable study results accepted worldwide.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
Assessment and Planning in Educational technology.pptxKavitha Krishnan
In an education system, it is understood that assessment is only for the students, but on the other hand, the Assessment of teachers is also an important aspect of the education system that ensures teachers are providing high-quality instruction to students. The assessment process can be used to provide feedback and support for professional development, to inform decisions about teacher retention or promotion, or to evaluate teacher effectiveness for accountability purposes.
5. Good Laboratory Practice (GLP) is a quality system
concerned with the organizational process and the
conditions under which non-clinical health and
environmental safety studies are planned, performed,
monitored, recorded, archived and reported
5
6. WHY WAS GLP CREATED?
• In the early 70’s FDA became aware of cases of
poor laboratory practice all over the United
States.
• They discovered a lot fraudulent activities and a
lot of poor lab practices.
1. Equipment not been calibrated to standard
form therefore giving wrong measurements.
2. Incorrect/inaccurate accounts of the actual lab
study.
3. Inadequate test systems. 6
7. • One investigation- made headline news
• Lab - IBT
• Mice that they had used to test developed cancer and died.
• IBT lab threw the dead mice and covered results deeming the
products good for human consumption.
• Those involved in production, distribution and sales for the lab
eventually served jail time
7
8. GLP was instituted in US following cases of fraud generated by
toxicology labs in data submitted to the FDA by pharmaceutical
companies. As a result of these findings, FDA promulgated the
Good Laboratory Practice (GLP) Regulations, 21 CFR part 58,
on December 22, 1978 (43FR 59986). The regulations became
effective on June 1979.
8
9. As an international standard:
In 1981 an organization named OECD produced GLP
principles that are international standards of the OECD
Council, data generated in the testing of chemicals in one
OECD Member Country, in accordance with OECD Test
Guidelines and the Principles of GLP are accepted in all
other OECD Member Countries
9
10. OECD
• An intergovernmental organization.
• Representatives of 30 industrialized countries in North America,
Europe, Pacific and the European Commission.
• To co-ordinate and harmonize policies, discuss issues of mutual
concern, and work together to respond to international problems
• The Principles of GLP have been developed to promote the quality
and validity of test data used for determining the safety of chemicals
and chemical products
10
11. OBJECTIVES OF GLP
• data submitted are a true reflection of the results that are
obtained during the study.
• not to indulge in any fraud activity by labs.
• international acceptance of tests
11
13. GOOD LABORATORY PRACTICE -
PRINCIPLES
1.Test Facility Organization and Personnel
2. Quality Assurance Program
3. Facilities
4. Apparatus, Material, and Reagents
5. Test Systems
6. Test and Reference Items
7. SOPs
8. Performance of the Study
9. Reporting of Study Results
10. Storage and Retention of Records and Materials
13
14. 1.Test Facility Organization and Personnel
A. Test Facility Management’s Responsibilities
B. Study Director’s Responsibilities
C. Principal Investigator’s Responsibilities
D. Study Personnel’s Responsibilities
14
15. A)Test Facility Management’s Responsibilities.
• Sufficient no. of qualified personnel, appropriate facilities,
equipment, and materials are available for the timely and
proper conduct of the Study
• Maintenance of a record of the qualifications, training,
experience.
• Job description for each professional and technical individual.
• Documented approval of the study plan by the Study Director.
15
16. B. Study Director’s Responsibilities.
• Approve the study plan.
• Any amendments to the study plan by dated Signature.
• Availability of SOPS to the personnel.
• Raw data generated are fully documented and recorded.
• Computerized systems used in the study have been validated.
• Sign and date the final report to indicate acceptance of responsibility for the
validity of the data.
• Ensure that after completion of the study, the study plan, the final report,
raw data and supporting material are archived.
16
17. C. Principal Investigator’s Responsibilities
Ensure that the delegated phases of the study are conducted in
accordance with the applicable Principles of Good Laboratory Practice
17
18. 2.Quality Assurance Program
1.Quality assurance personnel
2.Study plan contains the information-verification
3.conduct inspections
4.Records of such inspection should be retained
18
19. 3. Facilities
• Isolation of test systems and the isolation of individual projects involving
substances or organisms known to be or suspected of being bio hazardous.
• Areas as needed for supplies and equipment.
• Areas should be available for the diagnosis, treatment and control of diseases, in
order to ensure that there is no unacceptable degree of deterioration of test systems
Test system facilities
19
20. Archive Facilities
• Provided for the secure storage and retrieval of study plans,
raw data, final reports, samples of test items and specimens.
• Archive design and archive conditions should protect contents
from deterioration
20
21. Waste disposal
Handling and disposal of wastes should be carried out in such a
way as not to jeopardise the integrity of studies. This includes
provision for appropriate collection, storage and disposal
facilities, and decontamination and transportation procedures
21
22. 4. Apparatus, Material, and Reagents
• Apparatus, including validated computerized systems, used for the generation, storage
and retrieval of data, and for controlling environmental factors relevant to the study.
• Apparatus used in a study should be periodically inspected, cleaned, maintained, and
calibrated according to SOPs
• Apparatus and materials used in a study should not interfere adversely with the test
systems.
• Chemicals, reagents, and solutions should be labeled to indicate
identity, expiry date and specific storage instructions.
• Information concerning source, preparation date and stability should be available.
22
23. 5) Test Systems
• Physical and chemical test systems.
• Biological test systems.
• Records of source, date of arrival, and arrival conditions of test systems.
• Proper identification of test systems in their container or when removed.
• Cleaning and sanitization of containers.
• Pest control agents to be documented
23
24. 6. Test and Reference Items
• Receipt, handling, sampling and storage
• Characterization.
• Known stability of test and reference items.
• Stability of the test item in its vehicle (container).
• Experiments to determine stability in tank mixers used in the field studies.
• Samples for analytical purposes for each batch
24
25. 7.Standard Operating
Procedures (SOP)
• Written procedures for a laboratories program.
• They define how to carry out protocol specified activities.
• Most often written in a chronological listing of action steps.
• They are written to explain how the procedures are suppose to
work
25
26. • Routine inspection, cleaning, maintenance, testing and
calibration.
• Actions to be taken in response to equipment failure.
• Keeping records, reporting, storage, mixing, and retrieval of
data.
• Definition of raw data.
• Analytical methods
26
27. 8).Performance of the Study
A. Study Plan
B. Content of the Study Plan
C. Dates
D. Test Methods
E. Issues (where applicable)
F. Records.
G. A list of records to be retained.
H. Conduct of the Study.
27
28. STUDY PLAN
• Identification of the study, the test item and reference item.
• Information concerning the sponsor and the test facility.
• Dates
• Test Methods
• Records
28
29. CONDUCT OF THE STUDY
• A unique identification should be given to each study, all items concerning this
study should carry this identification
• Specimens from the study should be identified to confirm their origin.
• Conducted in accordance with the study plan
• Data generated should be recorded directly, promptly, accurately and signed
and dated
29
30. 9).Reporting of Study Results
• The final report should be signed and dated by the SD to indicate
acceptance of responsibility for the validity of the data.
• The extent of compliance with the principles of GLP should be indicated.
• Amendments should clearly specify the reason for the corrections or
additions and should be signed and dated by the SD
30
31. 10) Storage and Retention of Records
and Materials
• The study plan, raw data, samples.
• Inspection data and master schedules.
• SOPs.
• Maintenance and calibration data.
• If any study material is disposed of before expiry, the reason to be
justified and documented.
• Index of materials retained
31
32. What Good Laboratory Must
Contain.?
• Area should be free from smoke, smell, dust etc.
• Ensure good ventilation, proper illumination and prefer natural
light.
• Air conditioned the lab with humidity control.
• Enough space for measuring and testing instrument
32
33. • Proper arrangement of testing.
• Take care of all safety points including proper earthing as well
as fire safety.
• Avoid uncleanable spots in floors, walls, ceiling.
• Establish proper areas for storage of incoming samples as well
as test–completed samples.
• Also provide sample collection place as well as packing and
disposal of tested samples. 33
34. Do this for GLP
• Keep the things at its location after use.
• Store heavy things at bottom & if possible on Trollies.
• Give name of location to everything.
• Follow “Everything has the place & Everything at its place” principle.
• Prepare location list & display it.
• Put ladders for things stored on top.
• Identify everything with its name/ purpose.
• Follow “FIFO” to prevent old accumulation for
laboratory chemicals
34
35. Benefits of good laboratory
practices.
• It will give better image of company as a Quality producer in
Global market.
• Provide hot tips on analysis of data as well as measure uncertainty
and perfect record keeping.
• Provide guideline for doing testing and measurement in detail
• Provide guidelines and better control for maintenance of instruments,
environment control, preservation of test records etc
35
37. • National GLP-compliance Monitoring Authority was
established by the Department of Science & Technology
• Approval of the Union Cabinet on April 24, 2002
• A provisional member of the OECD for GLP.
• India is an Observer to the OECD’s Working Group on GLP
• The Authority has trained 33 experts in the country as GLP
inspectors
37
38. CONCLUSION
GLP is an FDA regulation which is accepted and
approved as international standards by OECD to
avoid the fraud activities of the testing laboratories for
pesticides , pharmaceuticals , food additives , dyes, to
save the human and environmental health and also erect
good international trade and establish good relationship
among the countries
38
39. REFERENCE
1) Good Laboratory Practice. By European Chemical Industry
Ecology and Toxicology Centre (ECETOC), Monograph No.
1,Brussels October 1979.
2) Good Laboratory Practice. by G.E. Paget, MTP Press
Limited, Lancaster 1979
39